Initial investment grows its U.S. operations and enhances its integrated drug substance, drug product intermediate, and drug product capabilities. Read More >>
Funding supports advancement of Excalipoint’s proprietary platforms and a pipeline of six differentiated programs with first- or best-in-class potential.
Brainin brings a combination of cardiovascular medicine, clinical research, and venture investing experience across EU and U.S. biotechnology companies.
New perfusion‑based adherent cell‑culture bioreactor is designed to scale cell therapy manufacturing with integrated process monitoring and automated harvesting.
